Kyverna Therapeutics (KYTX) Net Income towards Common Stockholders Growth (1y) (2024 - 2026)

Kyverna Therapeutics (KYTX) Net Income towards Common Stockholders Growth (1y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -88.68%
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -58.11%
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 104.24%
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -290.15%
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -129.68%
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -230.18%
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 59.59%
9 Abivax 90.15 Bn 90.15 Bn - -
10 Kyverna Therapeutics 492.54 Mn 259.59 Mn - 10.99%

Historic Data

Download Data
DateValue
Mar 31, 2026 10.99%
Dec 31, 2025 -0.87%
Sep 30, 2025 -6.64%
Jun 30, 2025 -46.14%
Mar 31, 2025 -67.28%
Dec 31, 2024 -81.70%
Sep 30, 2024 -122.93%
Jun 30, 2024 -119.96%
Mar 31, 2024 -139.38%